References
- Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1–4.
- Collom SL, Laddusaw RM, Burch AM, et al. (2008). CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem 283:3487–96.
- Crespi CL, Miller VP, Penman BW. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188–90.
- Dierks EA, Stams KR, Lim HK, et al. (2001). A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23–9.
- Friedman MA, Woodcock J, Lumpkin MM, et al. (1999). The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281:1728–34.
- He F, Bi HC, Xie ZY, et al. (2007). Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 21:635–43.
- Kozakai K, Yamada Y, Oshikata M, et al. (2014). Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms. Drug Metab Pharmacokinet 29:198–207.
- Li G, Huang K, Nikolic D, van Breemen RB. (2015). High-throughput cytochrome P450 cocktail inhibition assay for assessing drug–drug and drug–botanical interactions. Drug Metab Dispos 43:1670–8.
- Moody GC, Griffin SJ, Mather AN, et al. (1999). Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29:53–75.
- Ono S, Hatanaka T, Hotta H, et al. (1995). Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5:143–50.
- Otten JN, Hingorani GP, Hartley DP, et al. (2011). An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS. Drug Metab Lett 5:17–24.
- Wang JJ, Guo JJ, Zhan J, et al. (2014). An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes. J Pharm Anal 4:270–8.
- Yuan R, Madani S, Wei XX, et al. (2002). Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–9.